AWKN.F Stock Overview
A biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Awakn Life Sciences Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.095 |
| 52 Week High | CA$0.19 |
| 52 Week Low | CA$0.049 |
| Beta | 2.66 |
| 11 Month Change | 21.82% |
| 3 Month Change | -10.30% |
| 1 Year Change | 50.63% |
| 33 Year Change | -95.80% |
| 5 Year Change | n/a |
| Change since IPO | -93.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| AWKN.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.5% | 2.4% | 2.2% |
| 1Y | 50.6% | 16.2% | 31.7% |
Return vs Industry: AWKN.F exceeded the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: AWKN.F exceeded the US Market which returned 31.1% over the past year.
Price Volatility
| AWKN.F volatility | |
|---|---|
| AWKN.F Average Weekly Movement | 36.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AWKN.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AWKN.F's weekly volatility (36%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 6 | Anthony Tennyson | awaknlifesciences.com |
Awakn Life Sciences Corp., a biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavioural therapy (CBT) which is in phase 3 trials to treat severe Alcohol Use Disorder (AUD); AWKN-002, a novel MAT consisting of a patent pending proprietary S–ketamine oral thin film, and manualized relapse prevention CBT to treat AUD; and MDMA/Zydis, an investigational medicinal product entactogen that acts as a releaser and reuptake inhibitor of serotonin, norepinephrine, and dopamine. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD; with Graft Polymer (UK) PLC to develop chemical entity series programme for trauma-related mental health disorders; and with the University of Nottingham focusing on evaluating the company’s lead aminoindane series and its potential to enhance social cognition and pro-social behaviors.
Awakn Life Sciences Corp. Fundamentals Summary
| AWKN.F fundamental statistics | |
|---|---|
| Market cap | US$3.28m |
| Earnings (TTM) | -US$2.05m |
| Revenue (TTM) | US$58.97k |
60.7x
P/S Ratio-1.7x
P/E RatioIs AWKN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AWKN.F income statement (TTM) | |
|---|---|
| Revenue | CA$82.43k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$82.43k |
| Other Expenses | CA$2.95m |
| Earnings | -CA$2.87m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.069 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,479.83% |
| Debt/Equity Ratio | 0% |
How did AWKN.F perform over the long term?
See historical performance and comparison